IGC Pharma
8 hedge funds and large institutions have $151K invested in IGC Pharma in 2018 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
14% more funds holding
Funds holding: 7 → 8 (+1)
30% less capital invested
Capital invested by funds: $215K → $151K (-$64K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
+$11.5K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$2.06K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$25K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$20.1K |
| 3 |
VF
Virtu Financial
New York
|
-$12.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $57K | -$20.1K | -34,761 | -23% |
|
2
Creative Planning
Overland Park,
Kansas
| $32K | – | – | – |
|
|
SB
3
Suntrust Banks
Atlanta,
Georgia
| $27K | – | – | – |
|
|
VF
4
Virtu Financial
New York
| $22K | -$12.3K | -21,346 | -33% |
|
|
GWM
5
Geneos Wealth Management
Englewood,
Colorado
| $9K | +$11.5K | +20,000 | New |
|
|
6
UBS Group
Zurich,
Switzerland
| $2K | +$2.06K | +3,576 | New |
|
|
LTFS
7
Ladenburg Thalmann Financial Services
Miami,
Florida
| $1K | – | – | – |
|
8
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | – | – | – |
|
|
9
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$25K | -45,157 | Closed |
|
IGC Hedge Fund Activity: Q2 2018 in Review
8 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q2 2018, worth a combined $151K — down 30% from $215K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new IGC positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 2 trimmed.
The largest buyer was Geneos Wealth Management, opening a new position worth an estimated $11.5K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $25K sold.
- 8 institutional investors held IGC Pharma (IGC) as of Q2 2018, up from 7 in Q1 2018.
- Funds reported $151K of IGC Pharma stock for Q2 2018, down 30% quarter-over-quarter.
- 2 funds opened new IGC Pharma positions in Q2 2018 and 1 closed out, a net change of +1 holder.
- The largest IGC Pharma buyer in Q2 2018 was Geneos Wealth Management, an estimated $11.5K added.
- The largest IGC Pharma seller in Q2 2018 was Susquehanna International Group, an estimated $25K sold.
Based on aggregated 13F filings for Q2 2018.